FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Patients with suspected lung cancer will be able to access specialist diagnostic testing faster and closer to home following the launch of a new robotic bronchoscopy service at St Mary's Hospital, the first in north west London.
Imperial College Healthcare…
Attendees
Sponsors and Exhibitors
Contact us